Oppenheimer Holdings, Inc. started coverage on shares of BioLineRx Ltd. (NASDAQ:BLRX) in a research note published on Friday. The brokerage issued an outperform rating and a $3.00 price target on the biotechnology company’s stock.

BLRX has been the subject of several other reports. HC Wainwright set a $4.00 price target on BioLineRx and gave the company a buy rating in a report on Tuesday, April 18th. Zacks Investment Research lowered BioLineRx from a buy rating to a hold rating in a report on Friday, May 26th. Maxim Group set a $3.00 price target on BioLineRx and gave the company a buy rating in a report on Thursday, May 25th. ValuEngine upgraded BioLineRx from a sell rating to a hold rating in a report on Monday, July 17th. Finally, Roth Capital started coverage on BioLineRx in a report on Thursday. They set a buy rating and a $3.00 price target for the company. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock has a consensus rating of Buy and a consensus target price of $2.59.

BioLineRx (NASDAQ:BLRX) last announced its quarterly earnings results on Thursday, May 25th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by $0.03.

TRADEMARK VIOLATION WARNING: “BioLineRx Ltd. (BLRX) Earns Outperform Rating from Analysts at Oppenheimer Holdings, Inc.” was first published by Daily Political and is the property of of Daily Political. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.dailypolitical.com/2017/08/07/biolinerx-ltd-blrx-earns-outperform-rating-from-analysts-at-oppenheimer-holdings-inc.html.

A number of large investors have recently bought and sold shares of BLRX. Citadel Advisors LLC raised its stake in BioLineRx by 443.4% in the first quarter. Citadel Advisors LLC now owns 105,986 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 86,481 shares during the period. Renaissance Technologies LLC bought a new stake in BioLineRx during the first quarter valued at $126,000. Benchmark Capital Advisors raised its stake in BioLineRx by 227.3% in the first quarter. Benchmark Capital Advisors now owns 144,000 shares of the biotechnology company’s stock valued at $138,000 after buying an additional 100,000 shares during the period. KCG Holdings Inc. raised its stake in BioLineRx by 715.9% in the first quarter. KCG Holdings Inc. now owns 175,156 shares of the biotechnology company’s stock valued at $168,000 after buying an additional 153,687 shares during the period. Finally, Sabby Management LLC bought a new stake in BioLineRx during the first quarter valued at $3,018,000. Hedge funds and other institutional investors own 34.91% of the company’s stock.

About BioLineRx

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.

Analyst Recommendations for BioLineRx (NASDAQ:BLRX)

Receive News & Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.